Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG: Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia
NCT03010202Phase 3Completed
- Sponsor
- Ostfold Hospital Trust
- Start
- Jan 2017
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in immune thrombocytopenia (ITP), sponsored by Ostfold Hospital Trust. Started Jan 2017; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03010202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010202.